Cargando…
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?
[Figure: see text]
Autores principales: | Thavendiranathan, Paaladinesh, Sacher, Adrian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830213/ https://www.ncbi.nlm.nih.gov/pubmed/36636452 http://dx.doi.org/10.1016/j.jaccao.2022.11.010 |
Ejemplares similares
-
Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022) -
Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria
por: Wintersperger, Bernd J, et al.
Publicado: (2022) -
Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023) -
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
por: Lutgens, Esther, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression
por: Liu, Shiying, et al.
Publicado: (2020)